聚乙二醇干扰素（PEG-IFN）联合利巴韦林的联合疗法可诱发一名慢性丙型肝炎患者患1型糖尿病，但单独使用干扰素或聚乙二醇化干扰素均不会诱发。
Peginterferon (PEG-IFN) plus ribavirin combination therapy, but neither interferon nor PGE-IFN alone, induced type 1 diabetes in a patient with chronic hepatitis C.
作者信息
Ogihara Takehide, Katagiri Hideki, Yamada Tetsuya, Kudo Hirohito, Imai Junta, Ishigaki Yasushi, Hinokio Yoshinori, Yamagiwa Yoko, Ueno Yoshiyuki, Shimosegawa Tooru, Oka Yoshitomo
机构信息
Department of Diabetes and Metabolism, Tohoku University Hospital, Sendai.
出版信息
Intern Med. 2009;48(16):1387-90. doi: 10.2169/internalmedicine.48.2220. Epub 2009 Aug 17.
Interferon (IFN) therapies, including IFN, peginterferon (PEG-IFN) and ribavirin (RBV) plus PEG-IFN combination, are widely used for patients with chronic hepatitis C. We encountered a patient with chronic hepatitis C in whom previous IFN or PEG-IFN alone had not induced type 1 diabetes (T1D), while the addition of RBV to PEG-IFN did induce T1D. The patient had HLA types conferring highly susceptibility to T1D. Thus, adding RBV to PEG-IFN may render chronic hepatitis C patients, with T1D-susceptible HLA types, more prone to developing T1D than IFN or PEG-IFN alone. To prevent T1D development, we recommend HLA typing prior to initiating RBV plus PEG-IFN administration.
干扰素（IFN）疗法，包括IFN、聚乙二醇干扰素（PEG-IFN）以及利巴韦林（RBV）联合聚乙二醇干扰素的疗法，被广泛应用于慢性丙型肝炎患者。我们遇到一名慢性丙型肝炎患者，之前单独使用IFN或PEG-IFN均未诱发1型糖尿病（T1D），而在PEG-IFN基础上加用RBV却诱发了T1D。该患者具有对T1D高度易感的HLA类型。因此，相较于单独使用IFN或PEG-IFN，在PEG-IFN基础上加用RBV可能会使具有T1D易感HLA类型的慢性丙型肝炎患者更易发生T1D。为预防T1D的发生，我们建议在开始使用RBV联合PEG-IFN治疗前进行HLA分型。
Zotero 插件